Jump to content
RemedySpot.com

COMPANY OF THE YEAR: &

Rate this topic


Guest guest

Recommended Posts

by Niles

http://www.pharmalive.com/magazines/medad/view.cfm?articleID=2478

Leadership in major markets

& experienced its 72nd year of consecutive sales

growth in 2004. Last year marked the completion of two compete

decades of consecutive double-digit earnings increases, excluding

special charges. The company achieved a strong, balanced performance

in 2004, posting record results in sales, earnings, and cash flow.

J & J's medical-devices business segment will become much larger after

the completed acquisition by year-end 2005 of Guidant Corp., which

generated sales of $3.8 billion in 2004.

Sporanox, for fungal infections, generated 2004 sales of $655

million, an increase of 15.5% compared with 2003. In first-half

2005, sales for Sporanox were up 2% to $305 million, with a decrease

of 51.7% in U.S. markets.

Link to comment
Share on other sites

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...